Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor

Atrial Fibrillation Clinical Trial

— ASSERT-II  

Official title:

Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patient With Cardiovascular Risk Factors (ASSERT-II)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01694394
• Other study ID #: ASSERT-II
• Status: Completed
• Start date: December 2012
• Est. completion date: October 2016

Study information

• Verified date: August 2018
• Source: Population Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of the study is to determine the rate of detection of sub-clinical atrial fibrillation (≥ 5 minutes)within an average of 12 months following implant of the St. Jude Medical Confirm(R) Implantable Cardiac Monitor in patients with known cardiovascular risk factors and left atrial enlargement, but without prior AF.

Description:

Title of Study Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients with Cardiovascular Risk Factors (ASSERT-II) Short Title ASSERT-II Study Sponsor Population Health Research Institute (Grant in Aid from St. Jude Medical, Inc.) Principal Investigators Dr. J. Healey, Dr. S. Connolly, Dr. M. Alings Central Coordinating Centre Population Health Research Institute Recruitment and Participating Clinical Sites 250 patients from approximately 30 Sites Phase/Regulatory Status Phase IV - Cohort Study Hypothesis Among elderly patients with cardiovascular risk factors and a left atrial diameter ≥ 4.4 cm, but without prior clinical AF, an implanted continuous ECG monitor (St. Jude Medical Confirm® Implantable Cardiac Monitor) will detect subclinical AF (≥ 5 minutes in duration) in 12% or more of patients during an average follow-up of 12 months.

Study Objectives

Primary Objectives:

1. To determine the rate of detection of sub-clinical atrial AF (≥ 5 minutes) within an average of 12 months following implant of the St. Jude Medical Confirm® Implantable Cardiac Monitor in patients with known cardiovascular risk factors and left atrial enlargement, but without prior AF.

Secondary Objectives

1. To determine if the incidence of sub-clinical AF is higher among patients whose left atrial volume is above the median value observed in this study.

2. To determine the relationship between left atrial volume (continuous variable) and the risk of sub-clinical AF.

3. To evaluate other potential predictors of sub-acute AF in this population including:

baseline troponin-T, baseline NT-pro-BNP as well as clinical and other echocardiographic parameters.

4. To develop a preliminary economic analysis to evaluate the potential cost-effectiveness of screening this patient population with an Implantable Cardiac Monitor as a means of preventing stroke.

Study Design Cohort study to determine the prevalence of sub-clinical AF in an elderly population with common cardiovascular risk factors, such as hypertension and diabetes. Patients with echocardiographic evidence of atrial enlargement will be enrolled and have the St. Jude Medical Confirm® Implantable Cardiac Monitor (Confirm® ICM) subcutaneously implanted. To reduce costs, in most cases the implant will be done in conjunction with other planned surgery or heart catheterization.

PHRI: CONFIDENTIAL Final Version 2.0:2012-06-18 Page 4 of 24 Participants/Study Duration Total of 250 participants will be enrolled over 16 months. The last patient enrolled will have 9 months of follow-up, for a total study duration of approximately 25 months. Clinic visits will occur at enrolment and months 3, 6 and 9. A final visit will take place at 18 months of follow-up, or after the last patient enrolled has been followed for 9 months (whichever comes first).

Study Population Patients with known cardiovascular risk factors and left atrial enlargement, with no prior documented AF.

Intervention St. Jude Medical Confirm® Implantable Cardiac Monitor (Confirm® ICM) Enrollment and Follow-up Eligible and consenting patients will be enrolled and have the Confirm® ICM implanted. The implant may take place in conjunction with pre-planned non-cardiac surgery, heart catheterization, or as a stand-alone procedure. Follow-up visits will occur at month 3, 6 and 9. A final visit will take place at 18 months of follow-up, or after the last patient enrolled has been followed for 9 months (whichever comes first).

Assessment of Outcome Events An independent central adjudication committee comprised of arrhythmia experts will evaluate device-detected AF episodes.

Statistical Methodology Determine the incidence of sub-clinical atrial AF (≥ 5 minutes) using the Confirm® ICM.

Date of Protocol June 18, 2012

Recruitment information / eligibility

• Status: Completed
• Enrollment: 256
• Est. completion date: October 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria

Patients will be eligible for inclusion if they meet both of the following:

1. Age = 65, plus:

• CHA2DS2-VASc score = 2 Or

• Obstructive sleep apnea (documented by polysomnography, ambulatory oximetry, positive Berlin Questionnaire or requiring the use of CPAP/BiPAP) Or

• BMI > 30

2. Echocardiographic or biochemical evidence of increased risk of AF:

• Left atrial enlargement on a clinical echocardiography at any time prior to enrollment ( defined as LA volume = 58 ml or LA diameter of = 4.4 cm) Or

• Serum NT-ProBNP = 290 pg/mL Exclusion Criteria

1. Previously documented history of atrial fibrillation or atrial flutter 2. Current chronic treatment with oral anticoagulation (i.e. those on peri-operative prophylaxis would be eligible) 3. Patient with implanted pacemaker or defibrillator with an atrial lead 4. Definitive plan for cardiac surgery in the next 6 months (patients who are having coronary angiography with a possibility of cardiac surgery are still eligible)

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• Implantable Cardiac Monitor (Confirm ICM model 2102)
Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.

Locations

Country	Name	City	State
Canada	University of Calgary	Calgary	Alberta
Canada	Queen Elizabeth-II Heather Sciences Center	Halifax	Nova Scotia
Canada	Hamilton Health Sciences - Electrophysiology Clinic	Hamilton	Ontario
Canada	Hamilton Health Sciences - Interventional Cardiology	Hamilton	Ontario
Canada	Hamilton Health Sciences - Perioperative Ischemia Research Group	Hamilton	Ontario
Canada	London Health Sciences Center University Hospital	London	Ontario
Canada	McGill University Health Centre	Montreal	Quebec
Canada	Southlake Regional HealthCare	Newmarket	Ontario
Canada	University of Ottawa Heart Institute	Ottawa	Ontario
Canada	Institut Universitaire de Cardiologie et de Pneumologie de Quebec (Hopital Laval)	Sainte-Foy	Quebec
Canada	Health Sciences North	Sudbury	Ontario
Canada	University Health Network	Toronto	Ontario
Canada	St. Boniface Hospital	Winnepeg	Manitoba
Netherlands	Academisch Medisch Centrum (AMC) Amsterdam	Amsterdam
Netherlands	Amphia Hospital	Breda
Netherlands	Nij Smellinge	Drachten
Netherlands	Groene Hart Ziekenhuis Gouda	Gouda
Netherlands	Diakonessenhuis Leiden	Leiden
Netherlands	Ikazia Hospital	Rotterdam

Sponsors (3)

Lead Sponsor	Collaborator
Population Health Research Institute	Canadian Institutes of Health Research (CIHR), St. Jude Medical

Countries where clinical trial is conducted

Canada,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	First atrial fibrillation episode at least 5 minutes in duration	incidence of atrial fibrillation detected by continuous monitoring by an implantable cardiac monitor	over maximum follow-up of 18 months